Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
HIV tests, diabetes tech and a new CGM: inside Trinity Biotech's 2026 overhaul
Trinity Biotech (TRIB) updated on Q4 2025 trading and business progress, projecting Q4 2025 revenue of $11.5M–$12.5M, a decrease from Q4 2024 due to HIV testing market disruptions and manufacturing transitions. Despite this, the company highlighted positive developments such as regulatory approval to outsource Uni-Gold manufacturing, growing demand for its rapid HIV tests, IFCC Gold classification for its HbA1c solution, and ongoing development of new products like CGM+, EpiCapture, and PrePsia. The market reacted positively, with TRIB stock gaining 5.10% following the news, reflecting investor confidence in the company’s long-term transformation strategy.